eClinical Technology and Industy News

Paragon Genomics NGS Panel Captures New SARS-CoV-2 Mutations

Excerpt from the Press Release:

Paragon Genomics, Inc., a leader in amplicon-based target enrichment solutions for next-generation sequencing (NGS) and precision medicine, today announced a solution for capturing the new mutations of the SARS-CoV-2 variants that have been sweeping across the United Kingdom and South Africa, and already finding its way in various countries worldwide.

The new UK (20B/501Y.V1, VOC 202012/01, or B.1.1.7 lineage) and South African (20C/501Y.V2, or B.1.351 lineage) SARS-CoV-2 variants contain mutations in the receptor binding domain (RBD) of the spike protein, leading to concern and alarm worldwide. Several EU countries have issued travel bans within the UK in an effort to stop the new variant from spreading further. Officials in both the UK and South Africa have said that these mutations are driving the countries’ resurgence of the disease, with higher numbers of confirmed cases, hospitalizations and deaths.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?